MARCELLA POMERANZ: Open Payments
NPI 1174064083 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$7,641 in 104 payments from 15 companies in 2025. Trend: 2023 $2,120 · 2024 $1,550 · 2025 $7,641
Speaker / faculty: $5,475Food & beverage: $2,082Education: $84
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 28 | $3,520 |
| Ardelyx, Inc. | 8 | $2,739 |
| Lucid Diagnostics Inc. | 1 | $241 |
| ABBVIE INC. | 11 | $195 |
| PFIZER INC. | 12 | $174 |
| Aimmune Therapeutics, Inc. | 8 | $162 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $152 |
| GENZYME CORPORATION | 14 | $140 |
| Celltrion USA Inc. | 5 | $96 |
| Regeneron Healthcare Solutions, Inc. | 2 | $47 |
Products named: TREMFYA, IBSRELA, STELARA, DUPIXENT, XIFAXAN, SKYRIZI, VELSIPITY, VEGZELMA.
Industry payments across NV — which companies pay providers there.
